ESH 2017 | Tackling CD47-positive malignancies
Ravi Majeti
• 12 Oct 2017
Innovative research has begun to create a novel therapy that could potentially treat a variety of malignancies, including acute myeloid leukemia (AML). In this interview, Ravindra Majeti, MD, PhD, from Stanford University, Stanford, CA discusses the critical role of CD47 and how it can be utilized to treat AML. Dr Majeti then describes the progress of exciting work using humanized antibodies to inhibit CD47, including NCT02216409 and NCT02678338. This interview was recorded at the International Conference of Acute Myeloid Leukaemia 2017 in Estoril, Portugal by the European School of Hematology (ESH).
